Steris stock extends its medical device focus

Steris stock keeps its medical and life sciences franchise at the center as investors look to the latest reported operating and financial metrics from the Dublin group.

Steris plc (IE00BFY8C754) remains a closely watched medical technology name, with its latest reported numbers still defining the share story. The Dublin-based company reported fiscal 2025 revenue of $5.47 billion and adjusted EPS of $8.68, while fiscal 2025 free cash flow reached $827.0 million.

Fiscal 2025 sets the base

The fiscal 2025 revenue figure of $5.47 billion gives a clear scale reference for Steris stock, and adjusted EPS of $8.68 shows the earnings power behind that revenue base. Free cash flow of $827.0 million in fiscal 2025 adds a third anchor for investors who track conversion rather than sales alone.

Those three figures matter because they frame the business before any newer catalyst is even added: revenue, earnings, and cash generation are all large enough to support a defensive market profile. The comparison also matters, because the year-end numbers are period-specific and can be read against future quarters when new reporting arrives.

Cash flow and margin matter

Steris has also highlighted recurring demand from healthcare and sterilization workflows, which makes the margin profile more important than headline growth alone. In fiscal 2025, the company’s adjusted EPS of $8.68 and free cash flow of $827.0 million suggest that the market will continue to focus on operating leverage and cash discipline.

For a stock like Steris, the most useful comparison is not a generic growth label but the relationship between revenue, earnings, and cash flow over a full fiscal year. That is why the fiscal 2025 set remains the cleanest current anchor available in this article: $5.47 billion, $8.68, and $827.0 million.

Medical devices stay central

The core business remains sterilization services, infection prevention, and related capital equipment for hospitals, manufacturers, and life sciences customers. That product mix matters because it ties Steris stock to procedure volumes, regulatory standards, and replacement demand rather than pure consumer cycles.

In practical terms, the product side explains why fiscal-year numbers can hold more meaning than short-term market noise. Revenue of $5.47 billion in fiscal 2025 and free cash flow of $827.0 million point to a business model where recurring demand and installed-base economics are central.

Trading level to watch

Without a fresh quoted market price in the search results, the most reliable market context here is the company’s fiscal 2025 reporting base rather than an intraday move. For investors, Steris stock is best read through that lens: $5.47 billion in revenue, $8.68 in adjusted EPS, and $827.0 million in free cash flow all date to fiscal 2025 and remain the latest clear operating frame.

Steris plc at a glance

• Company: Steris plc
• ISIN: IE00BFY8C754
• Ticker: NYSE: STE
• Trading venue: New York Stock Exchange
• Sector / Industry: Health Care / Health Care Equipment & Supplies
• Index membership: S&P 500
• Market capitalization: omitted
• Next earnings date: omitted